BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
about
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patientsBreast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysisBreast Cancer Genetic Counseling: A Surgeon's PerspectiveTumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapyFine tuning chemotherapy to match BRCA1 statusThe closely related RNA helicases, UAP56 and URH49, preferentially form distinct mRNA export machineries and coordinately regulate mitotic progressionRegulation of mitosis and taxane response by Daxx and Rassf1.BRCA1: a novel prognostic factor in resected non-small-cell lung cancerCustomized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerDEAD-box helicase DP103 defines metastatic potential of human breast cancers.BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.MTA1-mediated transcriptional repression of BRCA1 tumor suppressor geneThe DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer.Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.Drug therapy for hereditary cancersDNA damage response and spindle assembly checkpoint function throughout the cell cycle to ensure genomic integrity.BRCA mutation testing in determining breast cancer therapy.Mechanisms of resistance to cabazitaxel.Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response.Advances in breast cancer: pathways to personalized medicinePreoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature.Drug resistance and its significance for treatment decisions in non-small-cell lung cancer.Tumour suppressor genes in chemotherapeutic drug response.Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cellsTaxanes for the treatment of metastatic breast cancer.In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinaseDifferential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.The spindle assembly checkpoint: More than just keeping track of the spindle.Basal-like subtype and BRCA1 dysfunction in breast cancers.Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations.Hereditary ovarian cancer: biology, response to chemotherapy and prognosis.DNA-PKcs activates the Chk2-Brca1 pathway during mitosis to ensure chromosomal stability.Triple-negative breast cancer--current status and future directions.Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.
P2860
Q21144211-4189F1D1-3EFC-4F6F-B87B-ADD06FF5DE83Q21198839-7B131D43-8528-49A5-B1F0-C8F328722F3FQ26767380-D4CB5895-2D28-421B-B371-4A9102CDDF05Q26768521-129A842F-4AAC-44E7-9431-C103C9DB199EQ27694529-6B68102F-73BB-4DDD-9BA4-6C2BFE5BC962Q30496034-DDA37120-4255-431E-9D61-C3080351FA5EQ30574064-EE36838A-3BFE-4492-B6EA-D921293DED0EQ33305206-7FBDF901-6567-4ACA-AEA4-C6487778C597Q33438894-F6F0D7A4-C17A-4471-ABFF-5C0EEBAF7AEFQ33564013-5E655938-C110-4DE8-8834-4BE78F6CBB0FQ33704050-29F3A120-B8F7-4EFB-850E-1C1DD4FD428AQ34117601-9C29B38C-B965-45B7-813B-BA354C66233AQ34550974-06354922-D802-4C3A-870B-23377083B80DQ34579373-D5ACC4F6-77EE-4DD2-9CE9-C57D6A870892Q34699428-36014468-CC1E-413C-9620-6644AD384355Q34889172-C8CB5438-F187-44AF-8C0E-72361C4C20DEQ35038441-CA5FCD25-9D07-42D8-A8A6-223F346AE2B9Q35208929-B7351AB6-3D93-4997-8D31-3D536F19611AQ35610725-133DB97B-0094-4E49-A823-99E5E0AB5219Q35619225-26F5753C-DB9B-42B5-82BE-54B75ACF43B8Q35661531-C5F2F4E5-B80F-4E75-98AF-0ACED489C270Q35893417-01F85E77-84AC-418C-A816-130A4DFBCF46Q35951346-77A4F96F-5DF3-4EAD-87AC-7273B3470C6FQ35976084-5C9011DB-9FD9-4A53-996A-F530C60CB5DCQ36040613-D654D818-1E32-42CB-B5B0-AE754401E24EQ36083098-9CE7D14A-3615-4AB9-9CDB-773B6E608E67Q36265840-70C54D6F-67D0-4668-B369-5FC07EF42E35Q36364762-4A279EC6-7532-466C-850C-4A30B2BFD186Q36589778-60901FF3-3E6F-43FD-8DF5-1A8A41E1A42DQ36747293-CBF519F1-ADA7-48C6-AF54-D02792C14442Q37128739-73C74FBD-0592-4307-B47F-3897B94F1A2BQ37276575-9F277C3B-56C0-44E7-A522-548D4F939F08Q37306567-80F10E54-60EE-4D47-8323-23048203A9E8Q37349840-3003A0E5-E904-4656-ADF1-F1FF4AF436D0Q37538136-E9F14077-AA9B-4A7D-828A-47864289B827Q37585309-7EE9BCC6-40C5-4D8E-B80F-569F4E921BFEQ37614607-BAB86B3F-F742-4724-A2BC-9CAE62C54262Q37630082-66A998BF-0639-44D5-99C8-612C02D66D0FQ37677557-78BD235D-EEDC-480A-8CB8-B1FD1599B6D9Q37756959-9C6A3595-835D-468D-A98D-B2E0CF1F0307
P2860
BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
BRCA1 downregulation leads to ...... confers paclitaxel resistance.
@en
type
label
BRCA1 downregulation leads to ...... confers paclitaxel resistance.
@en
prefLabel
BRCA1 downregulation leads to ...... confers paclitaxel resistance.
@en
P2093
P356
P1433
P1476
BRCA1 downregulation leads to ...... confers paclitaxel resistance.
@en
P2093
P304
P356
10.4161/CC.5.9.2726
P577
2006-05-01T00:00:00Z